Abstract library

230 results for "pulmonary carcinoids".
#2174 Clinicopathologic Features and Treatment Outcome of 225 Newly Diagnosed Pulmonary Carcinoids: A Single Center Experience of 28 Years
Introduction: Data on pulmonary carcinoids are scarce.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: M.D. Hong Zhao
Authors: Li Q, Zhou Y, Zhang Y, Chi Y, ...
#737 Impact of Ki-67 Proliferative Index on Survival in Patients with Typical and Atypical Pulmonary Carcinoids
Introduction: Currently pulmonary carcinoids are separated into typical and atypical tumors based on mitotic count and presence of necrosis, according to the WHO classification. Whereas for GEP NETs the ENETS Guidelines have been incorporated into the WHO classification and grading is based on mitotic counts and Ki-67 index, the use of the Ki-67 index for grading pulmonary carcinoids is still under debate.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Martina Rudelius
#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids
Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Diana Bello Roufai
#2129 Phosphohistone H3 (PHH3) Immunohistochemical Staining Outperforms Conventional H&E Mitotic Count in Classifying Pulmonary Carcinoids
Introduction: Pulmonary carcinoids (PC) are well-differentiated NETs and are classified as typical carcinoid (TC) and atypical carcinoid (AC). Despite the fact that TC and AC exhibit significant differences in patient survival, their classification depends on relatively subtle differences in mitotic count (MC). Although careful counting of mitotic figures (MF) is essential, it is a very subjective task, time-consuming and lacks of sensitivity and interobserver reproducibility, due to selection bias of the hot spots, heterogeneous distribution of MF, difficulty in distinguishing MF from similar chromatin changes (i.e. in apoptotic cells or due to crush, karyorrhectic debris, pyknosis or apoptosis).
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Dr Tu Vinh Luong
#146 Recurrence characteristics in resected pulmonary typical and atypical carcinoids
Introduction: Pulmonary typical and atypical carcinoids are widely considered indolent, although they can metastasize even with a very long relapse free interval. No standard follow-up strategy exists after a radical resection.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Michela Squadroni
#1518 Significance of Preoperative FDG-PET/CT Scan in Patients with Pulmonary Carcinoid Tumours
Introduction: FDG uptake on PET/CT scan has been shown to be of prognostic significance in patients (pts) with metastatic neuroendocrine tumours (NET).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Georgios Papaxoinis
#65 Deletions of 11q21-q25 are associated with atypical lung carcinoids and a poor clinical outcome
Introduction: Lung carcinoids comprise a group of smoking-unrelated neuroendocrine tumors, which can be classified in typical (TC) and atypical (AC) carcinoids. Classification is complex and its accuracy to predict disease outcome is variable. In a previous array comparative genomic hybridization (arrayCGH) study, we showed that the average number of chromosomal alterations (≥ 1Mb) was significantly higher in ACs than in TCs (512 v. 226 per tumor) and that the most common region of chromosome loss was 11q21-q25 (Neuroendocrinology 2009;90:136-137).
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MSc Dorian RA Swarts
#1499 Efficacy of the Combination of Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours
Introduction: Limited treatment options exist for patients (pts) with advanced pulmonary carcinoids (PC). Capecitabine-temozolomide (CAPTEM) has demonstrated significant efficacy in pts with pancreatic neuroendocrine tumours. However, its role in PC remains unexplored.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis
#2029 Prognostic Factors of Pulmonary Carcinoid Tumors
Introduction: Pulmonary carcinoids (PC) are rare malignant neoplasms that account for approximately 1% of all lung cancers. PCs are classified by histological criteria as either typical (TC) or atypical (AC). Histological subtype is the most studied prognostic factor.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MSc Tiina Vesterinen
#653 Interobserver Variability of Pulmonary Carcinoids
Introduction: Lung carcinoids are neuroendocrine tumors histopathologically classified into typical (TC; no necrosis, <2 mitoses/2 mm2) and atypical (AC; necrosis or 2-10 mitoses/2 mm2). Identification of mitoses may be hampered by the presence of apoptotic cells, and reported prediction of prognosis based on histopathology varies, especially for ACs.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MSc Dorian Swarts